sabato, 18 settembre 2021
2 Ottobre 2018

FDA Approves Cemiplimab for CSCC

September 28, 2018 – The FDA has approved the PD-1 inhibitor cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation. The approval is based on a combined analysis of data from the phase II EMPOWER-CSCC-1 (Study 1540) trial and 2 advanced CSCC expansion cohorts from a phase I trial (Study 1423). The … (leggi tutto)